Testimony Before the FDA’s Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee Regarding Brexpiprazole
View complete testimony as PDF
In testimony before the Food and Drug Administration’s (FDA’s) Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA not approve brexpiprazole for the treatment of agitation in patients with Alzheimer’s disease because the drug’s small benefits do not outweigh its significant risks.